Pulmonary Function and Structure Abnormalities in Children and Young Adults with Osteogenesis Imperfecta Point to Intrinsic and Extrinsic Lung Abnormalities
Overview
Authors
Affiliations
Purpose: Pulmonary disease is the major cause of morbidity and mortality in osteogenesis imperfecta (OI). We investigated the contribution of intrinsic lung factors to impaired pulmonary function in children and young adults with OI types III, IV, VI.
Methods: Patients with type III (n=8), IV (n=21), VI (n=5), VII (n=2) or XIV (n=1) OI (mean age 23.6 years) prospectively underwent pulmonary function tests (PFTs) and thoracic CT and radiographs.
Results: PFT results were similar using arm span or ulnar length as height surrogates. PFTs were significantly lower in type III than type IV or VI OI. All patients with type III and half of type IV OI had lung restriction; 90% of patients with OI had reduced gas exchange. Patients with variants had significantly lower forced expiratory flow (FEF)25%-75% compared with those with variants. PFTs correlated negatively with Cobb angle or age. CT scans revealed small airways bronchial thickening (100%, 86%, 100%), atelectasis (88%, 43%, 40%), reticulations (50%, 29%, 20%), ground glass opacities (75%, 5%, 0%), pleural thickening (63%, 48%, 20%) or emphysema (13%, 19%, 20%) in type III, IV or VI OI, respectively.
Conclusion: Both lung intrinsic and extrinsic skeletal abnormalities contribute to OI pulmonary dysfunction. Most young adult patients have restrictive disease and abnormal gas exchange; impairment is greater in type III than type IV OI. Decreased FEF25%-75% and thickening of small bronchi walls indicate a critical role for small airways. Lung parenchymal abnormalities (atelectasis, reticulations) and pleural thickening were also detected. Clinical interventions to mitigate these impairments are warranted.
Trial Registration Number: NCT03575221.
Lung function in adult patients with osteogenesis imperfecta: a cohort study.
Lenoir A, Aubry-Rozier B, Bregou A, Rodriguez E, Paquier C, Tanniger J Orphanet J Rare Dis. 2024; 19(1):455.
PMID: 39627862 PMC: 11616175. DOI: 10.1186/s13023-024-03452-y.
Bone Quality and Mineralization and Effects of Treatment in Osteogenesis Imperfecta.
Misof B, Fratzl-Zelman N Calcif Tissue Int. 2024; 115(6):777-804.
PMID: 39231826 DOI: 10.1007/s00223-024-01263-8.
Update on the Genetics of Osteogenesis Imperfecta.
Jovanovic M, Marini J Calcif Tissue Int. 2024; 115(6):891-914.
PMID: 39127989 PMC: 11607015. DOI: 10.1007/s00223-024-01266-5.